<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345953</url>
  </required_header>
  <id_info>
    <org_study_id>P13-04 / BP 1.4979</org_study_id>
    <secondary_id>2013-004884-30</secondary_id>
    <nct_id>NCT03345953</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome</brief_title>
  <acronym>P13-04</acronym>
  <official_title>Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Group Sequential Test multicenter, randomized, double blind, placebo controlled
      phase II proof of concept trial with parallel groups to evaluate the efficacy and the safety
      of BP1.4979 15mg BID compared to placebo in RLS patients during 2 weeks double blind
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periodic Limb Movements per hour of Sleep (PLMS index)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measure of the difference from baseline (Randomization) to the end of the double blind treatment period in Periodic Limb Movements per hour of Sleep (PLMS index) measured with PolySomnoGraphy (PSG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IRLSRS (International Restless Legs Syndrome Rating Scale)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in IRLSRS score measured at randomization and end double blind study.treatment period. IRLSRS is ranging from 0 (no symptoms) to 40 (very severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periodic Limb Movement during Wakefulness (PLMW)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in PLMW measured at randomization and end double blind study treatment period. The PLMW will be measured during a Suggested Immobilization Test (1-hour test) to evaluate the limb movements during wakefulness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by AEs collection</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Safety and tolerability of BP 1.4979 as assessed by AEs collection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">91</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>BP 1.4979</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg tablet BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP 1.4979</intervention_name>
    <description>Double blind versus placebo</description>
    <arm_group_label>BP 1.4979</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind versus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females &gt; or = to 18 years

          -  18 kg/m2 ≤ BMI ≤ 35 kg/m2

          -  Diagnosis of idiopathic RLS based on medical history and the presence of the 5 RLS
             diagnostic criteria and a normal clinical examination

               1. An urge to move the legs usually but not always accompanied by, or felt to be
                  caused by, uncomfortable and unpleasant sensations in the legs.

               2. The urge to move the legs and any accompanying unpleasant sensations begin or
                  worsen during periods of rest or inactivity such as lying down or sitting.

               3. The urge to move the legs and any accompanying unpleasant sensations are
                  partially or totally relieved by movement, such as walking or stretching, at
                  least as long as the activity continues.

               4. The urge to move the legs and any accompanying unpleasant sensations during rest
                  or inactivity only occur or are worse in the evening or night than during the
                  day.

               5. The occurrence of the above features is not solely accounted for as symptoms
                  primary to another medical or a behavioral condition.

          -  The condition is not better explained by another current sleep disorder, medical or
             neurological disorder, mental disorder, medication use, or substance use disorder.

          -  RLS severity score &gt; or = to 21/40 and RLS occurring at least 3 times per week for 'de
             novo' patients or after RLS treatment wash-out.

          -  Periodic Limb Movements during Sleep index &gt; 15 for 'de novo' patients or after RLS
             treatment wash out.

          -  Not taking or accepting to discontinue drug therapy or medication for RLS,
             antipsychotic medication, antidepressant including Selective Serotonin Reuptake
             Inhibitors (SSRIs) prescribed for at least 5 half-lives prior to randomization (e.g.
             fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram,
             venlafaxine, milnacipran, duloxetine) and/or any other psychotropic medication
             benzodiazepine and/or anticonvulsivants (gabapentine, pregabaline) prescribed to
             relief RLS, for at least 5 half-lives prior to randomization and/or opiates.

          -  Females of child-bearing potential must use a medically accepted effective method of
             birth control, agree to continue this method for the duration of the study and be
             negative to serum pregnancy test performed at the screening visit. Females should not
             be breast-feeding. Males accept to use child conception prevention method for the
             whole duration of the study

          -  In the opinion of the investigator, the subject must have adequate support to comply
             with the entire study requirements as described in the protocol (e.g. transportation
             to and from trial site, self-rating scales, drug compliance, scheduled visits, etc).

          -  Patient must have voluntarily expressed willingness to participate in this study,
             understand protocol procedures and have signed and dated an informed consent prior to
             beginning any protocol required procedures.

        Exclusion Criteria:

          -  Any significant psychiatric illness (schizophrenia, bipolar disorder, severe
             depression, dementia, obsessive compulsive disorder...) or mood disorder, assessed by
             the Beck Depression Inventory (BDI) (exclusion if &gt; or = to 16 and/ or item G ≠ 0).

          -  Abnormal neurological examination, history or presence of chronic pain other than that
             associated with RLS. History of epilepsy or serious head injury. History of peripheral
             neuropathy.

          -  Clinically significant sleep apnea (Apnea Hypopnea Index &gt;15), narcolepsy, parasomnia
             as an adult, circadian rhythm disorder, or secondary causes of RLS (e.g chronic renal
             failure/hemodialysis).

          -  Other active clinically significant illness, including unstable cardiovascular, or
             neoplasic pathology which could interfere with the study conduct or counter-indicate
             the study treatments, place the subject at risk during the trial or interfere with
             study assessments or compromise the study participation.

          -  Subject with a known history of long QTc syndrome (e.g. syncope or arrhythmia) or
             presenting any significant serious abnormality of the ECG (e.g. recent myocardial
             infarction), or QTcB interval strictly higher than 450 ms.

          -  Subject with moderate hepatic impairment (transaminases &gt; 1.5 ULN) or with renal
             impairment (creatinine clearance &lt; 90 mL/min) , or with any other significant
             abnormality in the physical examination or clinical laboratory results (e.g positive
             laboratory test for Hepatitis B surface antigen (HBsAg), or anti-HIV 1/2 or anti- HCV
             antibodies).

          -  Iron deficiency (ferritin &lt; 50 µg/l).

          -  Known hypersensitivity to the tested treatment including active substance and
             excipients.

          -  Use of drugs likely to influence sleep architecture or motor manifestations during
             sleep prior to randomization without an appropriate wash-out period. These include
             neuroleptics, L-dopa, dopamine agonists, hypnotics, sedatives, anxiolytics,
             antidepressants, anticonvulsants, psychostimulant medications, steroids in the
             evening, barbiturates, benzodiazepine treatment and opiates to relief RLS.

          -  Patient taking any prescription drug containing amphetamines.

          -  Recent history (≤ 1 year) of alcohol or drug abuse, or current evidence of substance
             dependence or abuse as defined by DSM-IV criteria (Gebauer L, LaBrie R et al. 2010).

          -  Regular consumption of large amounts of xanthine-containing substances (i.e more than
             5 cups of coffee or equivalent amounts of xanthine-containing substance per day).

          -  Patient participating in another study and the use of any investigational therapy
             within the 30 days prior to the entry in this study.

          -  Patient without any medical care insurance.

          -  Pregnant woman or a pregnancy detected with a positive serum pregnancy test performed
             at the screening visit or lactating female.

          -  Male patient who wants to conceive a child for the whole duration of the study.

          -  Patient under guardianship who cannot provide consent on his own.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad Ghorayeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pellegrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Lecomte, MD</last_name>
    <phone>+33 1 47 03 66 30</phone>
    <email>i.lecomte@bioprojet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Rodriguez</last_name>
    <phone>+33 1 47 03 66 30</phone>
    <email>p.rodriguez@bioprojet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Neurophysiology Department - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imad Ghorayeb, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

